Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 702.98

-3.1%

Nov 19 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	1/22/2018 6:38:03 PM
	Read Replies (1) of 3559

Odyssey outcome (CVOT) to be featured as late-breaker at ACC-18 (Saturday, 3/10): accscientificsession.acc.org While Rapatha CVOT did well on Stroke/MI....Praluent need to do significance on "all cause mortality" and CV events, to change needle in marketing/sales success. Core results should come out end-Jan/mid-Feb (my speculation).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next